# Catherine J. Wu

Source: https://onco.cc/people/catherine-wu/  
OnCo record `catherine-wu` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the first personalised neoantigen peptide vaccine trial in melanoma and mapped how CLL evolves under treatment.

## Summary

Catherine Wu led the 2017 Nature trial of NeoVax, a personalised neoantigen peptide vaccine that induced durable T-cell responses in melanoma patients, published alongside Şahin's mRNA work as the founding evidence for individualised cancer vaccines. Her laboratory also defined the clonal evolution of chronic lymphocytic leukaemia and its driver mutations. She directs transplantation and cellular therapies at Dana-Farber.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: vaccine; neoantigen; genomics
- Role: Chief, Division of Stem Cell Transplantation and Cellular Therapies, Dana-Farber Cancer Institute; Professor, Harvard Medical School
- Specialisms: Neoantigen vaccines; Cancer genomics; CLL evolution; Tumour immunology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20CJ%5BAuthor%5D%20neoantigen%20vaccine

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- institutions: [Broad Institute of MIT and Harvard](https://onco.cc/institutions/broad-institute/), [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)

---
JSON: https://onco.cc/api/v1/entities/catherine-wu.json